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Effects of platelet-rich fibrin on healing 
of intra-bony defects treated with 
anorganic bovine bone mineral
Abstract: Anorganic bovine bone mineral (ABBM) is extensively 
used in the treatment of intra-bony defects. Platelet-rich fibrin (PRF) 
is a new-generation platelet concentrate with a simplified technique. 
Although certain studies have reported the use of PRF in the treatment 
of intra-bony defects, to date, none of them have evaluated its additive 
effects with ABBM. Therefore, a randomised, split-mouth clinical 
trial was conducted to compare healing of intra-bony defects treated 
with an ABBM-PRF combination with healing of those treated with 
ABBM alone. By using a split-mouth design, 15 paired intra-bony 
defects were randomly treated with either ABBM alone (control group) 
or ABBM-PRF combination (test group). Following clinical parameters 
and radiographical measurements were recorded at baseline and 
6 months after treatment: plaque index (PI), gingival index (GI), probing 
depth (PD), gingival recession (GR), clinical attachment level (CAL), 
vertical bone loss, depth of defect and defect angle. Preoperative clinical 
and radiographical measurements were similar for the test and control 
groups. Statistically significant reductions in GI, PD, CAL, vertical bone 
loss, depth of intra-bony defect and widening of defect angle were 
detected after treatment in both groups. With respect to inter-group 
analysis, gain in CAL was significantly greater in the test group than 
in the control group, whereas no inter-group differences were observed 
in any other parameter. The results of this study indicate that both 
therapies are effective in the treatment of intra-bony defects.
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Introduction
The risk of further alveolar bone loss and the probability of tooth 
loss increases with the presence of intra-bony defects. Hence, treatment 
of intra-bony defects comprises several treatment modalities aimed to 
reconstruct the attachment apparatus which includes bone grafts, guided 
tissue regeneration, biomolecular techniques, or combination of some of 
these approaches.1
Over the years, various types of graft materials, including autogenic 
bone, demineralised allogenic bone, xenogeneic materials and alloplastic 
materials, have been used to regenerate the attachment apparatus. 
Among xenogeneic materials, anorganic bovine bone mineral (ABBM) 
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is a widely researched and well-documented 
grafting material.1 ABBM is produced by removal 
of all organic components of cancellous or cortical 
bovine bone. It can be safely used as no systemic or 
local immune response was observed after ABBM 
implantation.2 Histologically, new bone, cementum 
and new periodontal ligament formation have been 
observed in periodontal defects treated with ABBM.3,4 
Considering its aforementioned properties, ABBM 
has been successfully used in regenerative treatment 
of intra-bony and furcation defects.1,5
In recent years, researchers have focused on 
biological mediators which have the ability to 
enhance wound healing and improve clinical benefits 
of bone replacement grafts.6 Polypeptide growth 
factors are biological mediators which regulate cell 
proliferation, chemotaxis and differentiation and 
induce periodontal regeneration.7
To deliver high concentrations of polypeptide 
growth factors to periodontal surgical wounds, 
use of autologous platelet concentrates serve as a 
safe and appropriate approach. Various platelet 
concentrates have been developed to improve soft 
and hard tissue healing.8 Platelet-rich fibrin (PRF) is 
a second-generation platelet concentrate, defined as 
autologous leukocyte- and platelet-rich fibrin because 
it collects leukocytes and platelets with high efficiency. 
PRF has been demonstrated to release polypeptide 
growth factors such as transforming growth factor β1, 
platelet-derived growth factor, vascular endothelial 
growth factor and matrix glycoproteins (such as 
thrombospondin-1) gradually over at least 1 week.8,9
PRF has been used in different surgical procedures 
such as sinus floor augmentation, treatment of 
gingival recession (GR), furcation defects, maxillary 
rehabilitation before implant placement, restoration of 
peri-implant defects, as well as healing of extraction 
sockets with promising results.10,11,12,13,14 In addition, 
certain clinical studies have been conducted on the 
use of PRF for treatment of intra-bony defects in 
humans,15,16,17,18,19 but none have investigated its additive 
effects with ABBM for treatment of intra-bony defects. 
Thus, the present split-mouth, single-centre, controlled 
study aimed to compare the healing of intra-bony 
defects treated with a combination of ABBM-PRF 
or ABBM alone; the hypothesis being tested was 
that PRF would augment the regenerative effects of 
ABBM in human intra-bony defects.
Methodology
Patient selection and experimental design
Participants were recruited form patients referred 
to the Department of Periodontology, Gazi University, 
Turkey, and were enrolled after receiving detailed 
description of the procedures and providing signed 
informed consent. The study protocol was approved 
by the ethics board at the Faculty of Dentistry, Gazi 
University (2010/78). This parallel-arm clinical trial 
was registered at ClinicalTrials.gov (NCT02836314) 
and was conducted in accordance with the Helsinki 
Declaration of 1975, as revised in 2000. As far as 
possible, the CONSORT 2010 guidelines for reporting 
parallel-group randomised trials were followed.20 
All patients complained about generalised, severe, 
chronic periodontal disease, classified as generalised 
when >30% of sites were affected by a clinical 
attachment level (CAL) loss of ≥5 mm.21 The inclusion 
criteria of the study were as follows: no systemic 
diseases; a good level of oral hygiene (OH) (plaque 
index [PI] < 0.15); presence of two paired, two- or 
three-wall intra-bony defects with a probing depth 
(PD) of ≥6 mm and an intra-bony component of 
≥3 mm, as detected on radiographs; no intra-bony 
defects extending into the furcation area; tooth 
mobility ≤1; tooth and adjoining teeth testing vital 
and without symptoms or signs of endodontic 
involvement; and tooth and adjoining teeth free of 
caries or inadequate restorations.
Exclusion criteria included the following: patients 
with compromised immune systems; pregnant and/or 
lactating women; patients taking any drug known 
to affect the periodontal status or the coagulation 
system; and smokers.
This clinical study was a randomised controlled 
trial with a split-mouth design. The selected sites 
were randomly (coin toss) divided into control (ABBM 
alone) and test (ABBM-PRF) groups.
Pre-surgical therapy
Before surgery, each patient received cause-related 
periodontal treatment consisting of OH instructions, 
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motivation, full-mouth supra- and sub-gingival 
scaling and root planning. In cases diagnosed with 
trauma from occlusion, occlusal adjustment was 
performed. Four weeks after phase I periodontal 
therapy (baseline), periodontal re-evaluation was 
performed to confirm suitability of the sites for the 
surgical study.
Intra-examiner reproducibility
Two periodontists performed all surgeries. 
One examiner other than the surgeons performed 
all clinical measurements, and another examiner 
performed all radiographical measurements. Both 
examiners were blinded to the study groups. Before 
surgery, both examiners evaluated pre-surgical 
measurements from five patients and five digital 
radiographs twice, 48 hours apart. Calibration was 
accepted if ≥90 of the recordings could be reproduced 
within a 1-mm difference.
Clinical measurements
Following clinical parameters were assessed 
at baseline and 6 months after surgery by using a 
periodontal probe (Nordent Manufacturing Inc., 
Illinois, USA) by a calibrated investigator other 
than the surgeons who performed the surgeries: PI, 
gingival index (GI), PD, CAL and GR.22-23 All clinical 
measurements were recorded with the aid of an 
acrylic stent, for which, occlusal acrylic stents were 
fabricated and grooves were placed to standardise 
the position of the periodontal probe.
Radiographical measurements
Standardised radiographical examination 
was simultaneously conducted with clinical 
measurements. Radiographs were taken using 
long-cone parallel and direct digital radiography. 
An x-ray-sensitive intra-oral digital radiography 
sensor (RVG 5000, Eastman Kodak, Rochester, NY, 
U.S.A), an optimal standardisation and paralleling 
system (XCP-DS®, Sendor Positioning System for 
Kodak Trophy RVG® Digital Sensors, Dentsply 
Rinn® Dentsply Int, Inc.) and digital imaging 
software (Sigma Scan Pro 5 Diagnostic Systems, 
Dept. Oral Radiology/ACTA, Amsterdam, Holland) 
were used. Site-specific individual bite stents 
were prepared from silicone elastomeric material 
(Zetaplus, Zhermack, Rovigo, Italy) for optimal 
localisation of the sensor positioning system in 
each defect area. The following parameters were 
assessed:
a. Vertical bone loss: distance between 
cemento-enamel junction and base of the defect 
(CEJ-BD) (Figure 1);24
b. Depth of intra-bony defect (DD): distance 
between alveolar crest and base of the defect 
(AC-BD) (Figure 1);25
c. Radiographical defect angle: by using the 
function ‘angle’, the defect angle was measured 
by assessing the two lines which represent the 
root surface of the involved tooth and the bone 
defect surface (Figure 1).26
Surgical therapy
Following local anaesthesia, buccal and lingual 
sulcular incisions were made, and mucoperiosteal 
flaps were elevated. The flap was extended one or 
two teeth mesially or distally to achieve better access 
to the surgical site. Granulation tissue was removed 
from the defects, and the roots were scaled and planed 
using hand instruments; however, the root surfaces 
were not conditioned.
In the test group, blood samples were obtained 
according to the PRF protocol which was developed 
by Choukroun et al. and immediately centrifuged 
at 2,700 rpm for 12 minutes (approximately 400 g) 
by PC-02 table centrifuge, specifically designed for 
this application (Process, Nice, France).27 PRF clots 
were easily separated from red corpuscles base 
by using sterile tweezers and scissors and then 
transformed into fibrin membranes by using the 
PRF Box (Process, Nice, France), designed to collect 
and standardise PRF clots and membranes in order 
to avoid extracting and losing a significant amount 
of growth factors.28 One PRF was cut by scissors to 
produce small pieces and then mixed with ABBM 
granules with a particle size of 0.25–1 mm (Bio-Oss, 
Gesitlich, Switzerland) in a sterile dappen dish; 
this mixture was added to the defect by means of a 
sterile curette. The defect was filled to the existing 
alveolar crest. The other PRF was used to cover the 
defect as a barrier.
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In the control group, ABBM was prepared by 
pouring the particles into a sterile dappen dish and 
rehydrated with sterile saline, and graft material 
was placed on the defect; the defect was filled to the 
existing alveolar crest.
Primary soft tissue closure was obtained using 
4–0 silk suture, and periodontal dressing was placed 
over the surgical area to achieve haemostasis and 
wound stability in both groups.
Post-surgical care
Patients were instructed to avoid brushing and 
flossing at the surgical site until the sutures and 
periodontal dressing were removed. All patients 
were prescribed systemic antibiotics (doxycycline: 
200 mg on the day of surgery and 100 mg/day 
thereafter for 14 days) and 0.2% chlorhexidine 
gluconate rinses (every 12 hours for 4 weeks). 
Patients were also prescribed oral analgesics 
(paracetamol 100 mg, as needed). The periodontal 
dressing and sutures were removed 1 week after 
surgery. Surgical areas were cleansed with 0.12% 
chlorhexidine digluconate, and patients were 
advised gentle brushing with a soft toothbrush. 
Patients were examined weekly up to 1 month after 
surgery and then at 2, 3 and 6 months.
Statistical analysis
Descriptive statistics were expressed as mean 
± standard deviation (SD). Statistical analysis was 
performed using a software program (Minitab 
version 16.1.1, USA). The normality of values was 
tested using the Anderson–Darling test. PD, CAL, 
GR, vertical bone loss, depth of the intra-bony defect 
and radiographical defect angle values were normally 
distributed and compared using paired samples t-test 
within each group and between groups at baseline and 
at 6 months. GI and PI variables were not normally 
distributed, and the Wilcoxon test was used to detect 
significant differences within and between groups 
at baseline and at 6 months. p values < 0.05 were 
considered statistically significant.
Sample size calculation
Sample size calculation suggested that a minimum 
of 14 patients were needed to demonstrate a 1 mm 
difference in CAL between the two groups after 
treatment (90% power, α of 0.05, SD of 1.06).17 
Figure 1. Measurements of vertical bone loss and radiographical defect angle with digital radiography imaging software.
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Considering the dropout rate, to achieve at least 
14 patients, a total sample of 21 patients were enrolled 
in this study.
Results
Of the 30 screened patients, 21 eligible participants 
who provided consent were randomised into test (n = 21) 
or control (n = 21) groups and 15 patients completed 
the study (7 women and 8 men; age: 38–61 years). Five 
patients were excluded on account of defects which did 
not meet the study criteria at the time of surgery, and 
one patient did not return for the follow-up examination 
(Figure 2). All sites healed uneventfully with no clinically 
detectable or subjectively reported side effects.
The defects displayed comparable distribution 
in the two groups (Table 1). Initial clinical and 
radiographical measurements were similar in both 
test and control groups, and no statistical difference 
was observed between the groups (p > 0.05) (Table 2).
The difference in PI scores at baseline and 
6 months after treatment was not significant in 
Figure 2. Consort flow chart of the study.
21 elligible subjects randomly allocated to the
- Test group (ABBM-PRF)
- Control group (ABBM alone)
Excluded because the patients did not 
meet the inclusion criteria (n = 9)
Test group
21 subjects
Baseline 
Excluded because the defects did not 
meet the study criteria at surgery (n = 5)
 
Lost to follow up because 
did not return for the 
follow-up examınation (n = 1)
6 month 
 
Control group
15 subjects
 Test group
15 subjects
 
Analysis Analyzed (n = 15)Analyzed (n = 15)
Control group
21 subjects
Screened patients (n = 30)
Table 1. Distribution of treated defects (n = 15).
Defect Location Test group Control group
Maxilla 8 6
Mandible 7 9
Anterior teeth 6 6
Premolars 7 6
Molars 2 3
Table 2. Baseline clinical and radiographical measurements.
Parameter Test group Control group
PI 0.07 ± 0.25 0.13 ± 0.35
GI 0.93 ± 0.59 0.94 ± 0.01
PD (mm) 7.46 ± 1.19 7.07 ± 1.03
GR (mm) 0.87 ± 0.91 0.66 ± 0.72
CAL (mm) 8.33 ± 1.76 7.73 ± 1.16
Vertical bone loss (mm) 8.44 ± 2.13 8 ± 1.71
Depth of the defect (mm) 4.33 ± 0.93 3.64 ± 0.93
Defect angle (º) 37.87 ± 5.25 41.37 ± 5.92
Values are presented as mean ± standard deviation; PI: plaque 
index; GI: gingival index; PD: pocket depth; GR: gingival recession; 
CAL: clinical attachment level.
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any group, whereas this difference in GI scores 
was significant in both groups (p < 0.05; Table 3). 
Moreover, PD decreased significantly compared to 
baseline at 6 months after treatment in both groups 
(p < 0.05), but the inter-group differences were not 
statistically significant at any evaluation time point 
(p > 0.05; Table 4).
In terms of CAL gain, both groups demonstrated 
significant improvements compared to baseline. 
In inter-group analysis, significantly greater CAL 
gain was detected in the test group than in the control 
group (p < 0.05; Table 4).
In addition, increase in GR was not statistically 
significant at 6 months after treatment compared to 
baseline (p > 0.05) in the test group, whereas this 
increase was statistically significant in the control 
group (p < 0.05); however, the inter-group difference 
in these increases was not statistically significant at 
any evaluation time point (p > 0.05; Table 4).
According to hard tissue findings, both treatment 
groups showed significant improvements compared 
to baseline in terms of vertical bone gain, defect fill 
and defect angle at 6 months after treatment (p < 0.05; 
Figures 3 and 4).
Table 3. Plaque index and gingival index scores in both groups.
Parameter Baseline test group 6 Months test group Baseline control group 6 Months control group
PI 0.0 7 ± 0.25 0.13 ± 0.35 0.13 ± 0.35 0.13 ± 0.35
GI 0.93 ± 0.59 0.27 ± 0.46* 0.94 ± 0.01 0.28 ± 0.01*
PI: plaque index, GI: gingival index; *statistically significant difference compared to baseline (p < 0.05).
Table 4. Mean and standard deviation of clinical and radiographical measurements in both groups.
Parameter Baseline 6 months Difference p-value
PD (mm) 
Test group 7.46 ± 1.19 2.53 ± 0.74* 4.93 ± 1.22 < 0.001
Control group 7.07 ± 1.03 2.86 ± 1.12* 4.21 ± 1.21 < 0.001
p-value NS NS NS  
GR (mm)
Test group 0.87 ± 0.91 1.33 ± 0.82 0.46 ± 0.83 NS
Control group 0.66 ± 0.72 1.60 ± 0.63* 0.94 ± 0.70 < 0.001
p-value NS NS NS  -
CAL (mm) 
Test group 8.33 ± 1.76 3.86 ± 1.19* 4.47 ± 1.60¶ < 0.001
Control group 7.73 ± 1.16 4.46 ± 1.35* 3.27 ± 1.34¶ < 0.001
p-value NS NS < 0.05  -
Vertical Bone Loss (mm)
Test group 8.44 ± 2.13 4.08 ± 1.09* 4.36 ± 2.42 < 0.001
Control group 8 ± 1.71 4.06 ± 0.91* 3.94 ± 1.69 < 0.001
p-value NS NS NS  -
Depth of the Defect (mm)
Test group 4.33 ± 0.93 1.78 ± 0.39* 2.55 ± 1.15 < 0.001
Control group 3.64 ± 0.93 1.66 ± 0.42* 1.98 ± 0.80 < 0.001
p-value NS NS NS  -
Defect Angle (º)
Test group 37.87 ± 5.25 51.15 ± 4.02* 13.28 ± 8.27 < 0.001
Control group 41.37 ± 5.92 53.09 ± 4.03* 11.72 ± 6.83 < 0.001
p-value NS NS NS  -
*statistically significant difference between the groups (p < 0.05)
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differences were not statistically significant between 
the two groups. Döri et al.30 compared ABBM with 
ABBM-PRP in human intra-bony defects and reported 
no significant differences between the two treatment 
groups. In the first year, PD reduction was 5.2 mm 
for the test group and 5.3 mm for the control group. 
In another controlled clinical comparative study31 
conducted by Döri et al.30 the PD reduction was 
6.20 mm for the control group and 6.60 mm for the 
test group at 9 months after surgery. These reductions 
were greater than those obtained in the present study. 
Conversely, Richardson et al.32 compared ABBM to 
demineralised, freeze-dried bone allograft (DFDBA) 
in human intra-bony defects and 6 months after 
surgery, the PD reduction was 3 mm for the ABBM 
group, which are lower compared to the reductions 
obtained in the present study. This discrepancy 
could be attributed to the differences in terms of 
study design, re-evaluation period, inclusion criteria, 
initial soft tissue measurements, initial defect depth 
and intra-bony defect configuration.33
In the control group, the increase in GR was 
statistically significant compared to baseline, whereas 
in the test group, this increase was not statistically 
significant compared to baseline; this could be 
attributed to placement of the PRF membrane over 
the alveolar crest in the test group. In this way, PRF 
acts as a healing and inter-position biomaterial owing 
to its mechanical adhesive properties and biological 
functions similar to fibrin glue.34
Discussion
The present randomised clinical trial compared 
the use of ABBM alone (control group) to ABBM-PRF 
combination (test group) in surgical treatment of 
intra-bony defects. Statistically significant reductions 
in GI, PD, CAL, vertical bone loss, depth of the 
intra-bony defect and widening of the defect angle were 
detected after treatment in both groups. GR increased 
significantly in the control group, whereas this increase 
was not significant in the test group. According to 
inter-group analysis, only CAL gain was statistically 
significant in the test group compared to the control 
group, whereas other parameters did not show 
significant inter-group differences.
To the best of our knowledge, to date, there have 
been no published reports which compare clinical 
and radiographical effects of ABBM with those of 
ABBM-PRF in the treatment of periodontal intra-bony 
defects. Thus, a direct comparison with other studies 
was not possible.
At baseline, none of the measured clinical and 
radiographical variables showed any significant 
inter-group differences, thus ensuring the same 
starting point for both procedures and the prevention 
of selection bias.29
In the present study, mean PD decreased from 
7.46 ± 1.19 mm to 2.53 ± 0.74 mm at the test sites 
and from 7.07 ± 1.03 mm to 2.86 ± 1.12 mm at the 
control sites at 6 months after surgery; however, these 
Figure 3. Test group: (A) periapical radiograph of the intra-bony 
defect at baseline; (B) periapical radiograph of the intra-bony 
defect at 6 months after ABBM-PRF combination treatment.
A B
Figure 4. Control group: (A) periapical radiograph of the 
intra-bony defect at baseline; (B) periapical radiograph of the 
intra-bony defect at 6 months after ABBM treatment.
A B
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A greater and statistically significant CAL gain was 
noted in the test group (4.47 ± 1.60 mm) compared to 
the control group (3.27 ± 1.34 mm) at 6 months after 
surgery. As described earlier, by using PRF membrane 
in the test group, GR remained stable after surgery, 
whereas it increased significantly in the control group. 
The significant CAL gain observed in the test group 
could be explained by the achievement of lesser GR at 
6 months after surgery owing to use of PRF membrane.
In terms of vertical bone gain, the results of this 
study compare favourably with those reported in 
previous human studies with ABBM.32, 35 Conversely, 
the reduction in the depth of the defect obtained in 
the present study is lower compared to the reductions 
observed in a previous study which reported a 3.8-mm 
defect fill at the 18-month evaluation of defects 
treated with a DFDBA-PRP combination.36 This can 
be attributed to the difference in the re-evaluation 
period, graft material and initial defect depth.
Klein et al.37 reported a defect angle gain of 12.81º in 
intra-bony defects treated with GTR. Similarly, Ilgenli 
et al.36 reported a defect angle gain of 10.8º at 18 months 
after surgery in intra-bony defects treated with a 
DFDBA-PRP combination. In the present study, the 
defect angle increased from 37.87 ± 5.25º to 51.15 ± 4.02º 
in the test group and from 41.37 ± 5.92º to 53.09 ± 4.03º 
in the control group. These results are in concordance 
with those of the aforementioned studies.36,37
Several studies15,16,17,38 have examined the suitability 
of autologous PRF for treatment of human intra-bony 
defects and revealed that PRF improves clinical15 and 
radiographical15,16,17,38 parameters. However, in the 
present study, no statistically significant differences 
were observed between both groups, except for the 
significant CAL gain noted in the test group. This 
discrepancy is likely because of the disparity of the 
study designs. In previous studies, the control groups 
were treated with conventional open-flap debridement 
alone or with PRF, whereas in the present study, 
the control group was treated with ABBM. ABBM is 
an extensively researched material which has been 
successfully used alone for treatment of intra-bony and 
furcation defects, with a positive role in reducing PD, 
promoting CAL gain and enhancing defect fill in 
periodontal defects.3,4,5,32 The positive results of the 
control group (ABBM alone) are in accordance with 
findings from previous studies which had failed to 
show significant differences between treatment with 
ABBM alone or combinations of ABBM with enamel 
matrix derivative or platelet-rich plasma (PRP).30,39 
Although the results of this study suggest that 
treatment with ABBM-PRF may not have provided 
significantly better results than those obtained with 
ABBM alone, the possibility for PRF to show any 
beneficial effects over the control group might have 
been masked by the fact that treatment with ABBM 
alone resulted in significant improvement.
The present study has several important strengths. 
It was designed as a split-mouth study to maintain 
a powerful estimate of treatment effect with a 
smaller sample size and discard individual patient 
characteristics. In addition, different examiners blinded 
to study groups performed all clinical and radiological 
measurements. Moreover, by using Choukroun’s 
protocol to obtain PRF and by using PRF Box when 
transforming PRF clots to PRF membrane are some of 
the other strengths of this study. Choukroun’s protocol 
does not require anticoagulants or bovine thrombin 
but requires a PC-02 table centrifuge and a collection 
kit from Process (Nice, France); thus, PRF has the 
characteristic of polymerising naturally and slowly 
during centrifugation. This type of polymerisation 
facilitates PRF to progressively release growth 
factors which play essential roles in cell proliferation, 
chemotaxis and differentiation and induce periodontal 
regeneration.7,8,9 In order to avoid extraction and losing 
a significant amount of growth factors, Choukroun 
invented the PRF Box; this standardised and gentle 
compression approach allows an increase in the release 
of total growth factors by the PRF membrane.28 Both 
obtaining and compression methods influence the 
total amount and releasing profile of growth factors 
in PRF.27,28 Therefore, following Choukroun’s simple 
protocol principles is necessary to obtain reproducible 
and reliable results. However, our study also has certain 
limitations. The first limitation is the short evaluation 
period of 6 months. Moreover, lack of histological 
examination to evaluate the regenerative capacity of 
PRF and lack of evaluation of patient-reported outcomes 
may be rendered as study limitations.
In conclusion, results of this study suggest that both 
ABBM alone and ABBM combined with PRF can be 
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successfully used for treatment of intra-bony defects. 
On comparing sites treated with ABBM alone versus 
ABBM-PRF combination, no statistically significant 
differences were found in clinical and radiographical 
parameters, except for statistically significant CAL 
gain in the test group. The similar results observed 
in both groups can be attributed to two possible 
reasons: first, the use of ABBM alone in the control 
group might have masked any positive effects of 
PRF in the treatment; the second reason might be 
lack of evaluation of patient-reported outcomes and 
soft tissue characteristics. Patient perceptions could 
have been quantified by administering a self-report 
questionnaire by using a visual analogue scale (VAS) 
which tests for variables of pain, sensitivity, swelling 
and discomfort experienced during the procedures, 
whereas soft tissue characteristics could have been 
evaluated using pink aesthetic score. By evaluating 
these parameters, significant differences could have 
been detected. Thus, additional controlled studies are 
warranted in the future to evaluate patient-centred 
outcomes and soft tissue characteristics in order to 
confirm these results with larger samples and longer 
evaluation periods.
Conclusion
The results of this study indicate that both ABBM 
and ABBM-PRF interventions are effective in the 
treatment of intra-bony defects. However, addition of 
PRF to ABBM may lead to enhancement of CAL gain.
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